After adjusting for chronic HBV infection status, age, sex, smoking, and drinking, we found that the CTLA-4 rs231775 G>A polymorphism might decrease the risk of HCC (GA vs GG: adjusted OR = 0.74, 95% CI: 0.55–0.99, P = .042; AA vs GG: adjusted OR = 1.16, 95% CI: 0.73–1.84, P = .519; GA/AA vs GG: adjusted OR = 0.83, 95% CI: 0.63–1.09, P = .168 and AA vs GG/GA: adjusted OR = 1.34, 95% CI: 0.86–2.08, P = .193; Table 4). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.